Eukaryotic translation initiation factor 4A1 in the pathogenesis and treatment of cancers.
biomarkers
clinicopathologic features
eukaryotic translation initiation factor 4A1
human cancer
inhibitors
Journal
Frontiers in molecular biosciences
ISSN: 2296-889X
Titre abrégé: Front Mol Biosci
Pays: Switzerland
ID NLM: 101653173
Informations de publication
Date de publication:
2023
2023
Historique:
received:
06
09
2023
accepted:
09
10
2023
medline:
29
11
2023
pubmed:
29
11
2023
entrez:
29
11
2023
Statut:
epublish
Résumé
Abnormal translate regulation is an important phenomenon in cancer initiation and progression. Eukaryotic translation initiation factor 4A1 (eIF4A1) protein is an ATP-dependent Ribonucleic Acid (RNA) helicase, which is essential for translation and has bidirectional RNA unwinders function. In this review, we discuss the levels of expression, regulatory mechanisms and protein functions of eIF4A1 in different human tumors. eIF4A1 is often involved as a target of microRNAs or long non-coding RNAs during the epithelial-mesenchymal transition, associating with the proliferation and metastasis of tumor cells. eIF4A1 protein exhibits the promising biomarker for rapid diagnosis of pre-cancer lesions, histological phenotypes, clinical staging diagnosis and outcome prediction, which provides a novel strategy for precise medical care and target therapy for patients with tumors at the same time, relevant small molecule inhibitors have also been applied in clinical practice, providing reliable theoretical support and clinical basis for the development of this gene target.
Identifiants
pubmed: 38028556
doi: 10.3389/fmolb.2023.1289650
pii: 1289650
pmc: PMC10666758
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1289650Informations de copyright
Copyright © 2023 Huang, Zhang, Yang, Yao, Gou, Cao, Pan, Li, Pan and Zhang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Front Cell Dev Biol. 2021 Nov 19;9:711965
pubmed: 34869305
Genome Biol. 2019 Dec 30;20(1):300
pubmed: 31888698
Br J Cancer. 2002 Jun 17;86(12):1957-62
pubmed: 12085193
Cell. 2014 Sep 11;158(6):1281-1292
pubmed: 25215487
Mol Cancer Ther. 2021 Jan;20(1):26-36
pubmed: 33037136
Cancer Res. 2017 Feb 1;77(3):613-622
pubmed: 27879264
Nat Rev Clin Oncol. 2011 May;8(5):280-91
pubmed: 21364523
J Cancer. 2018 Nov 11;9(24):4568-4577
pubmed: 30588240
Nat Rev Mol Cell Biol. 2010 Feb;11(2):113-27
pubmed: 20094052
Nucleic Acids Res. 2023 Feb 28;51(4):1859-1879
pubmed: 36727461
Cancers (Basel). 2021 Mar 23;13(6):
pubmed: 33807050
PLoS One. 2010 Sep 30;5(9):
pubmed: 20941364
J Exp Clin Cancer Res. 2019 Feb 11;38(1):66
pubmed: 30744688
Cancer Manag Res. 2019 Nov 11;11:9553-9562
pubmed: 31807078
Mol Cancer Ther. 2019 Nov;18(11):2158-2170
pubmed: 31395685
Annu Rev Biochem. 2019 Jun 20;88:307-335
pubmed: 31220979
Commun Biol. 2019 May 3;2:165
pubmed: 31069274
Cancer Cell Int. 2021 Dec 14;21(1):670
pubmed: 34906136
J Mol Biol. 2011 Sep 30;412(4):674-87
pubmed: 21840318
RNA. 1999 Sep;5(9):1210-21
pubmed: 10496222
Nature. 2016 Jun 15;534(7608):558-61
pubmed: 27309803
Clin Cancer Res. 2018 Sep 1;24(17):4256-4270
pubmed: 29844128
Turk J Med Sci. 2020 Nov 25;51(2):661-674
pubmed: 33237662
Front Cell Dev Biol. 2021 Mar 15;9:647527
pubmed: 33791304
J Exp Clin Cancer Res. 2020 Jul 20;39(1):139
pubmed: 32690100
Tumour Biol. 2017 May;39(5):1010428317698389
pubmed: 28466778
Structure. 2021 Jul 1;29(7):638-639
pubmed: 34214439
Cold Spring Harb Perspect Biol. 2012 Jul 01;4(7):a013706
pubmed: 22751155
J Cell Biol. 2010 Feb 22;188(4):463-71
pubmed: 20156963
Structure. 2014 Jul 8;22(7):941-8
pubmed: 24909782
Cell Chem Biol. 2021 Apr 15;28(4):475-486.e8
pubmed: 33296667
Oncogene. 2008 Apr 3;27(15):2128-36
pubmed: 17968323
Biochem Soc Trans. 2014 Feb;42(1):166-72
pubmed: 24450646
Nucleic Acids Res. 2006;34(15):4168-80
pubmed: 16936318
Cell. 2016 Aug 11;166(4):963-976
pubmed: 27477511
Genome Biol. 2019 Dec 2;20(1):262
pubmed: 31791371
RNA. 2020 May;26(5):541-549
pubmed: 32014999
Mol Cell. 2019 Feb 21;73(4):738-748.e9
pubmed: 30595437
Phytochem Rev. 2022;21(3):725-764
pubmed: 34104125
Leukemia. 2021 Sep;35(9):2469-2481
pubmed: 34127794
Eur J Med Chem. 2020 Oct 1;203:112653
pubmed: 32693294
Cancers (Basel). 2020 Aug 04;12(8):
pubmed: 32759815
Oxid Med Cell Longev. 2021 Aug 9;2021:9674809
pubmed: 34422211
Int J Mol Sci. 2022 Jun 22;23(13):
pubmed: 35805935
Cell Death Differ. 2015 Apr;22(4):524-5
pubmed: 25613380
Science. 2015 Jun 26;348(6242):1486-8
pubmed: 26113725
Cancer Manag Res. 2020 Dec 03;12:12473-12485
pubmed: 33299354
J Nat Prod. 2005 Jun;68(6):880-5
pubmed: 15974612
Cell Chem Biol. 2019 Nov 21;26(11):1586-1593.e3
pubmed: 31519508
J Med Chem. 2020 Jun 11;63(11):5879-5955
pubmed: 32470302
J Invest Dermatol. 2021 Apr;141(4):742-753.e10
pubmed: 32971126
Cell Chem Biol. 2021 Jun 17;28(6):825-834.e6
pubmed: 33412110
Br J Cancer. 2012 Mar 27;106(7):1297-305
pubmed: 22415234
Nucleic Acids Res. 2014 Jul;42(12):7911-22
pubmed: 24848014
FEBS Lett. 2013 Jul 11;587(14):2266-71
pubmed: 23747307
Acta Biochim Biophys Sin (Shanghai). 2020 Mar 18;52(3):310-319
pubmed: 32147684
Nature. 2014 Sep 4;513(7516):65-70
pubmed: 25079319
Int J Gynecol Cancer. 2014 Jun;24(5):908-15
pubmed: 24844222
Nucleic Acids Res. 2019 Jun 4;47(10):5260-5275
pubmed: 30997503
Int J Mol Sci. 2020 Jun 20;21(12):
pubmed: 32575790
Cancer Res. 2008 Jul 1;68(13):5326-34
pubmed: 18593934
J Mol Biol. 2014 Jan 9;426(1):51-61
pubmed: 24080224
Cell Death Dis. 2015 Jan 22;6:e1603
pubmed: 25611378
Oncogene. 2022 May;41(19):2778-2785
pubmed: 35361883
PLoS One. 2022 Mar 22;17(3):e0265692
pubmed: 35316283
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
EMBO J. 2009 Feb 4;28(3):274-85
pubmed: 19153607
Sci Transl Med. 2017 May 10;9(389):
pubmed: 28490664
Onco Targets Ther. 2019 May 21;12:3965-3976
pubmed: 31190893
Neuro Oncol. 2016 Sep;18(9):1265-77
pubmed: 26951381